Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2013-04-04 AGM Information
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting of Medivir AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of Annual General Meeting of Medivir AB (publ)" and details the date, time, location, participation requirements, and the proposed agenda for the meeting. The agenda items cover standard AGM topics such as election of the chairman, approval of financial statements, discharge from liability, determination of director/auditor fees, and proposals for remuneration guidelines and share authorizations. This content perfectly matches the definition of an Annual General Meeting (AGM) notice/material.
2013-04-04 English
Kallelse till årsstämma i Medivir AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Medivir AB (publ)" which translates to 'Notice of Annual General Meeting in Medivir AB (publ)'. The text details the date, time, location, procedures for participation (shareholder registration, proxy voting), and a detailed agenda for the meeting. The agenda items (1 through 17) cover standard AGM topics like election of the chairman, approval of the annual report (item 7), dividend disposition (item 9), election of directors and auditors (items 11-13), and proposals regarding remuneration guidelines and incentive programs (items 15-17). This content is characteristic of a formal notice and materials distributed for an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2013-04-04 Swedish
New Drug Application has been filed with FDA for Simeprevir (TMC435) for combination treatment of adult patients with genotype 1 chronic hepatitis C
Regulatory Filings Classification · 95% confidence The document is a press release dated March 28, 2013, announcing that a New Drug Application (NDA) for the drug Simeprevir has been filed with the U.S. Food and Drug Administration (FDA). This announcement details a significant regulatory submission milestone and its financial implications (€10m milestone payment). This type of announcement, focusing on a specific regulatory action (filing an application) rather than the final approval or a comprehensive financial report, fits best under the general category of regulatory announcements or updates that are not covered by more specific codes like 10-K, ER, or IR. Since it is a specific regulatory update concerning a drug application, and not a general earnings release or a formal legal proceeding report, the most appropriate classification among the provided options is 'Regulatory Filings' (RNS), as it serves as a general regulatory announcement that doesn't fit the other specialized categories (like DIRS, DIV, or CAP). It is not a Call Transcript (CT), Earnings Release (ER), or Interim Report (IR).
2013-03-28 English
Registreringsansökan för Simeprevir (TMC435) har lämnats in till FDA för trippelbehandling av vuxna med kronisk hepatit C av genotyp 1
Regulatory Filings Classification · 95% confidence The document is a press release dated March 28, 2013, announcing that Medivir AB has submitted a New Drug Application (NDA) for its drug Simeprevir to the FDA for the treatment of chronic Hepatitis C. This announcement details a significant corporate/regulatory event (drug submission) and mentions a milestone payment received. This type of announcement, which is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT), but rather a specific corporate development update, fits best under the general category of Regulatory Filings (RNS) or potentially a Capital/Financing Update (CAP) due to the mention of the milestone payment strengthening the financial position. However, since it is a specific regulatory submission announcement, RNS is the most appropriate general regulatory fallback, as it doesn't fit the specific definitions for DVA, LTR, or SHA. Given the context of a major regulatory submission announcement, RNS is the best fit among the available options, as it is a general regulatory announcement.
2013-03-28 Swedish
Valberedningens förslag till ny styrelse inför årsstämman 2013
Board/Management Information Classification · 99% confidence The document is a press release dated March 21, 2013, announcing the Nomination Committee's proposal for the new Board of Directors ahead of the 2013 Annual General Meeting (Årsstämman). It details the proposed re-elections and new nominations for the board, including biographies of the proposed new members. This content directly relates to the composition of the board and the agenda/proposals for the AGM. While it is an announcement related to the AGM, the core subject matter is the proposed composition of the Board of Directors, which falls under Board/Management Information (MANG) or potentially AGM Information (AGM-R). Since it specifically details the *proposal* for the board structure leading up to the AGM, and the definitions for MANG cover 'Announcement of changes in the company's board of directors or senior management,' MANG is a strong fit. However, given the context is explicitly tied to the 'årsstämman' (AGM), AGM-R (AGM Information) is also highly relevant as these proposals are central to the AGM proceedings. Since the document is a formal announcement of the proposed board structure for the upcoming AGM, AGM-R is the most precise fit for materials presented or proposed for the Annual General Meeting. It is not a DEF 14A (Remuneration) or DVA (Voting Results). Given the explicit mention of the 'årsstämman 2013' and the proposal for the new board, AGM-R is selected.
2013-03-21 Swedish
Nomination Committee proposes new Board of Directors ahead of 2013 AGM
Board/Management Information Classification · 99% confidence The document is a press release dated March 21, 2013, titled "Nomination Committee proposes new Board of Directors ahead of 2013 AGM." It explicitly details the proposals made by the Nomination Committee regarding the re-election and new election of Board members for the upcoming Annual General Meeting (AGM). This content directly relates to the composition of the board and management structure, which aligns perfectly with the 'Board/Management Information' (MANG) definition. While it mentions the AGM, the core subject is the proposal for the board members, not the AGM materials themselves (AGM-R) or the voting results (DVA).
2013-03-21 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.